Article

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.

Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.8). 07/2011; 68(1):157-64. DOI: 10.1007/s00280-010-1470-2
Source: PubMed

ABSTRACT Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy.
Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study.
Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested.
Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.

0 Bookmarks
 · 
259 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is the most dreadful disease worldwide in terms of morbidity and mortality. The exact cause of cancer development and progression is not fully known. But it is thought that cancer occurs due to the structural and functional changes in the genes. The current approach to cancer treatment based on allopathic is expensive, exhibits side effects; and may also alter the normal functioning of genes. Thus, a safe and effective mode of treatment is needed to control the cancer development and progression. Some medicinal plants provide a safe, effective and affordable remedy to control the progression of malignant cells. The importance of medicinal plants and their constituents has been documented in Ayurveda, Unani medicine, and various religious books. Curcumin, a vital constituent of the spice turmeric, is an alternative approach in the prevention of cancer. Earlier studies have shown the effect of curcumin as an antioxidant, antibacterial, antitumor and it also has a noteworthy role in the control of different diseases. In this review, we summarize the understanding of chemopreventive effects of curcumin in the prevention of cancer via the regulation of various cell signaling and genetic pathways.
    BioMed Research International 09/2014; 2014:761608. DOI:10.1155/2014/761608 · 2.71 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mammalian target of rapamycin (mTOR) kinase plays an important role in regulating cell growth and cell cycle progression in response to cellular signals. It is a key regulator of cell proliferation and many upstream activators and downstream effectors of mTOR are known to be deregulated in various types of cancers. Since the mTOR signalling pathway is commonly activated in human cancers, many researchers are actively developing inhibitors that target key components in the pathway and some of these drugs are already on the market. Numerous preclinical investigations have also suggested that some herbs and natural phytochemicals, such as curcumin, resveratrol, timosaponin III, gallic acid, diosgenin, pomegranate, epigallocatechin gallate (EGCC), genistein and 3,3'-diindolylmethane inhibit the mTOR pathway either directly or indirectly. Some of these natural compounds are also in the clinical trial stage. In this review, the potential anti-cancer and chemopreventive activities and the current status of clinical trials of these phytochemicals are discussed.
    Asian Pacific journal of cancer prevention: APJCP 08/2014; 15(16):6463-6475. DOI:10.7314/APJCP.2014.15.16.6463 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is the fifth leading cause of cancer related deaths worldwide. Currently, finding an effective drug delivery strategy in pancreatic cancer treatment is a major challenge. Nanotechnology offers an indispensible function by precisely delivering anticancer therapeutics in a targeted method to the cancer specific cells thus sparing normal healthy cells and hence resulting in an enhanced efficiency. The development of designer multifunctional therapeutics with magnetic nanoparticles (MNP) is a promising approach to selectively deliver therapeutics and image them in cancer cells. This study explored the preparation, characterization and application of a targeted nanosystem represented by an aptamer conjugated dual drug (curcumin and gemcitabine-loaded) and MNP encapsulated PLGA nanoparticles (Apt-Cur-Gem-PLGA-MNPs) for pancreatic cancer therapy. The aptamer targeted NPs exhibited excellent antiproliferative activity leading to apoptosis owing to enhanced cellular uptake. The presence of MNP in the nanoconjugate was exploited for magnetic hyperthermia and magnetic ablation of cancer cells by a rotating magnetic field. Thus, Apt-Cur-Gem-PLGA-MNPs is able to deliver an effective and targeted delivery of therapeutics for pancreatic cancer treatment.
    RSC Advances 01/2013; 3(43):20579. DOI:10.1039/c3ra42645a · 3.71 Impact Factor

Full-text (2 Sources)

Download
105 Downloads
Available from
May 29, 2014